Time to Negative SARS-CoV-2 PCR Should Not Delay Care Among Patients With Inflammatory Bowel Diseases

Inflamm Bowel Dis. 2021 Mar 15;27(4):590-592. doi: 10.1093/ibd/izab023.
No abstract available

Keywords: COVID-19; Crohn disease; inflammatory bowel diseases; ulcerative colitis.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Anti-Inflammatory Agents / administration & dosage*
  • Anti-Inflammatory Agents / therapeutic use
  • Antibodies, Monoclonal, Humanized / administration & dosage
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • COVID-19 / complications
  • COVID-19 / diagnosis*
  • COVID-19 Nucleic Acid Testing*
  • Drug Administration Schedule
  • Female
  • Follow-Up Studies
  • Humans
  • Immunologic Factors / administration & dosage*
  • Immunologic Factors / therapeutic use
  • Inflammatory Bowel Diseases / complications
  • Inflammatory Bowel Diseases / drug therapy*
  • Janus Kinase Inhibitors / administration & dosage*
  • Janus Kinase Inhibitors / therapeutic use
  • Male
  • Middle Aged
  • Polymerase Chain Reaction
  • Retrospective Studies
  • Time Factors
  • Time-to-Treatment
  • Treatment Outcome
  • Young Adult

Substances

  • Anti-Inflammatory Agents
  • Antibodies, Monoclonal, Humanized
  • Immunologic Factors
  • Janus Kinase Inhibitors
  • vedolizumab